The P2 Receptors and Congenital Platelet Function Defects

Marco Cattaneo, M.D.

In the above-mentioned article, published in Seminars in Thrombosis and Hemostasis 2005; Volume 31, Number 2, pages 168–173, page 170, paragraph 1, line 3 should read:

P2Y12 is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel,2,32 which are already used in clinical practice, and the AR-C compounds,33 one of which is currently under evaluation in clinical trials.